|
WO2020171055A1
|
|
Benzazepine derivative alcoholate or crystal thereof
|
|
WO2020171073A1
|
|
Method for producing benzazepine derivative and intermediate of same
|
|
KR20200102420A
|
|
Immunochromatography device
|
|
JP2019058668A
|
|
Sampling device and rotary type powder compression molding machine
|
|
JP2019147756A
|
|
Stable novel erythrocyte production stimulation protein preparation
|
|
JP2019059675A
|
|
Pharmaceutical for prevention or treatment of diabetic neuropathy
|
|
JP2019043900A
|
|
Agent for treating constipation which contains lactulose as an active ingredient
|
|
JP2018118909A
|
|
Pharmaceutical composition containing pregabalin
|
|
JP2018035086A
|
|
Pharmaceuticals for preventing and/or treating hypoactive bladder
|
|
JP2016185993A
|
|
Method for producing 1-benzoyl-5-oxo-2,3,4,5-tetrahydro-1h-benzo[b]azepine-4-carboxylic acid ester
|
|
WO2016186184A1
|
|
Crystal of salt of novel 3-azabicyclo[3.1.0]hexane derivative and pharmaceutical use thereof
|
|
WO2016175092A1
|
|
Medicine for preventing or treating hepatocellular carcinoma
|
|
WO2016133069A1
|
|
Drug for preventing or treating cardiac failure
|
|
JP2016040338A
|
|
Method for producing 1-benzoyl-5-oxo-2,3,4,5-tetrahydro-1h-benzo[b]azepine-4-carboxylic acid ester
|
|
JP2016069382A
|
|
Pharmaceutical formulation comprising hmg-coa reductase inhibitor
|
|
JP2016199496A
|
|
Lactulose containing pharmaceutical composition
|
|
WO2015152319A1
|
|
Production method for 5,7-unsubstituted-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid
|
|
JP2016147827A
|
|
Pharmaceutical formulations containing lanthanum carbonate hydrate
|
|
JP2015143218A
|
|
Miglitol-containing solid preparation
|
|
JP2017122050A
|
|
Production method for 5,7-unsubstituted-pyrazolo[1,5-a]pyrimidine-6-carboxylic acid
|
